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Bipolar disorder is a highly heritable illness that onsets in adolescence and young adulthood. We examined
gene expression (mRNA) and protein levels of candidate immune and neurotrophic markers in well-characterized
offspring of bipolar parents in order to identify reliable indicators of illness risk status and the early clinical stages of
illness development. We measured mRNA expression and protein levels in candidate immune (TNF-α, IL-1β, IL-10,
IFN-δ) and neurotrophic (brain-derived neurotrophic factor (BDNF)) markers from plasma. High-risk offspring were
identified from families in which one parent had confirmed bipolar disorder. Control offspring were identified from
families in which neither parent met lifetime criteria for a major psychiatric disorder. All parental Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnoses were based on Schedule for Affective
Disorders - Lifetime Version (SADS-L) interviews and blind consensus review. As part of an ongoing study, all
offspring were prospectively assessed using KSADS-PL format interviews and diagnoses confirmed on blind
consensus review. High-risk offspring had significantly increased IL-6 (p = 0.050) and BDNF (p = 0.006) protein levels
compared to controls. Those high-risk offspring in earlier compared to later clinical stages of illness development
had higher IL-6 (p = 0.050) and BDNF (p = 0.045) protein levels. After adjustments, only differences in BDNF protein
levels remained significant. There was a moderating effect of the BDNF genotype on both gene expression and
protein levels in high-risk compared to control offspring. The BDNF genotype also moderated the association
between clinical stage and gene expression levels in high-risk offspring. These findings provide support for
detectable differences in candidate immune and neurotrophic markers in individuals at high risk of developing
bipolar disorder and for detectable changes over the clinical stages of illness development. These associations
appear to be moderated by genetic variants.
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There is convergent evidence from longitudinal studies
that bipolar disorder (BD) develops in a series of predict-
able clinical stages in those at genetic risk (Duffy et al.
2014). A developmental approach to diagnosis is well ac-
cepted and useful in other areas of medicine, improving
earlier accurate identification, providing the opportunity
to develop stage-specific treatments preventing the pro-
gression of disease (Scott et al. 2013). In order to refine
the clinical staging model and identify novel specific
early intervention targets, it is essential to understand
the pathophysiological processes associated with the clin-
ical stages of illness development (McGorry et al. 2010).
A large body of evidence supports the association be-
tween stress, clinically significant depression, and ac-
tivation of the immune and neuroendocrine systems
(Woiciechowsky et al. 1999; Berk et al. 2011; Gibney
and Drexhage 2013), although it still remains unclear if
differential reactivity to stress reflects a predisposition
or a marker of illness activity or both. The coexistence
of elevated circulating levels of pro-inflammatory cyto-
kines and cortisol in patients suffering from acute mood
episodes represents an abnormal state, as cytokines typ-
ically negatively feedback to decrease release of hypo-
thalamic corticotrophin-releasing factor which in turn
decreases cortisol levels (Connor and Leonard 1998).
However, clinical depression has been associated with a
failure of the normal inhibitory feedback pathway of
cortisol on cytokine secretion, in at least a subset of
patients (Woiciechowsky et al. 1999). Specifically, in
patients with established illness, hypothalamic-pituitary-
adrenal (HPA) activation is associated with acute exacerba-
tions as a state marker (Deshauer et al. 1999), and recent
evidence suggests that this defect in inhibitory feedback
resulting in both immune and HPA axis activation may be
a useful trait marker in high-risk individuals (Duffy et al.
2012; Halligan et al. 2007; Ellenbogen et al. 2011).
Specifically, Padmos et al. (2008) reported increased
mRNA expression in a series of genes relevant to inflam-
mation in BD adults and their offspring. Increased expres-
sion was especially evident in remitted offspring with a
lifetime history of depression or in those who went on to
develop a depressive episode shortly after sampling. As
summarized by Berk et al. (2011), an increase in pro-
inflammatory markers is associated with acute BD episodes
of both depressive and manic polarity. Interestingly, with
increasing illness episodes, there appear to be a persistent
perturbation in the balance of pro- and anti-inflammatory
cytokines (Kauer-Sant'Anna et al. 2009) and a decrease in
brain-derived neurotrophic factor (BDNF) suggestive of a
neuroprogressive course. Effective stabilization with lithium
has been associated with re-establishing the balance be-
tween pro- and anti-inflammatory markers and with neuro-
protection (Berk et al. 2011; Kapczinski et al. 2008; Hajeket al. 2013). Collectively, the findings suggest that at least in
a subset of individuals, subtle perturbations in neuroim-
mune markers may correlate with the early clinical stages
of illness development in high-risk individuals and serve as
an important early intervention target (Raison et al. 2010;
Maes et al. 2012).
In this paper, we present findings from a cross-sectional
study of DNA polymorphisms, mRNA expression, and
protein levels in candidate immune system (TNF-α, IL-1β,
IL-10, IFN-δ) and neurotrophic (BDNF) markers from
plasma collected in prospectively assessed high-risk off-
spring of well-characterized BD parents and from well off-
spring of psychiatrically unaffected parents (controls). The
markers were selected based on the most robust findings
in the literature (Padmos et al. 2008; Frey et al. 2013). We
tested the hypothesis that high-risk offspring would show
differences in the gene expression and protein levels of
candidate markers compared to controls. Secondly, we ex-
plored differences in gene expression and protein levels
associated with early compared to later stage illness devel-
opment in high-risk offspring using a previously published
staging model (Duffy et al. 2010, 2014). Finally, we ex-




The sample included 19 high-risk and 16 control offspring
with a mean age at sample collection of 21.89 (standard
deviation (SD) 4.04) and 20.44 (SD 2.61) years, respect-
ively. High-risk offspring had a mean GAF score of 86.11
(SD 8.12) and the control mean GAF score was 89.19 (SD
5.88) at the time of sampling. There were no significant
differences in SES, age, or sex between high-risk and con-
trol offspring (all p > 0.05). The distribution of variants for
each of the five markers studied was similar between
high-risk and control groups. As would be expected in a
high-risk cohort early in the developmental course of ill-
ness, the GAF scores were comparable to controls.
Clinical characteristics
For those high-risk offspring meeting operational criteria
for later stage illness development (major depression or
BD lifetime), the clinical characteristics are presented in
Additional file 1: Table S1. High-risk offspring who met
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV) criteria for a major mood dis-
order had a mean illness onset, as defined by age of first
meeting full diagnostic criteria for a major mood episode,
of 16.37 years (SD 4.86). The duration (weeks) of acute ill-
ness episodes before sampling in this subgroup of remit-
ted high-risk offspring was 41.57 weeks (SD 25.12). Only
two high-risk offspring were taking mood stabilizers and
no offspring was taking any other psychotropic at the time
Table 1 Unadjusted mRNA expression and protein levels of candidate markers between groups
High-risk vs. control offspring High-risk early vs. later clinical stage
Control n = 16 High-risk n = 19
p valuea
Early n = 12 Later n = 7
p valuebMean SD Mean SD Mean SD Mean SD
BDNF mRNA 0.1753 (0.2616) 0.2737 (0.3525) 0.5410 0.3464 (0.4403) 0.1593 (0.0635) 0.7346
Protein 105.13 (68.85) 234.83 (162.69) 0.0056 290.96 (152.59) 138.60 (140.03) 0.0453
TNF mRNA 0.2290 (0.2615) 0.4759 (0.8113) 0.2485 0.6521 (1.012) 0.1991 (0.1089) 0.4747
Protein 55.53 (20.07) 54.33 (12.28) 0.8292 56.22 (12.46) 51.09 (12.16) 0.3951
IFN mRNA 0.0388 (0.0688) 0.0615 (0.0658) 0.0803 0.0584 (0.0795) 0.0663 (0.0410) 0.2447
Protein 81.56 (26.80) 70.99 (28.70) 0.2715 63.36 (18.93) 84.09 (38.70) 0.1324
IL-6 mRNA 0.0740 (0.1063) 0.0966 (0.1956) 0.8091 0.0846 (0.2014) 0.1156 (0.2005) 0.3192
Protein 5.98 (1.62) 7.77 (3.18) 0.0505 8.84 (3.60) 5.92 (0.59) 0.0502
IL-10 mRNA 0.0549 (0.0521) 0.0836 (0.0779) 0.7390 0.0683 (0.0620) 0.1076 (0.0984) 0.7219
Protein 16.16 (8.82) 19.36 (6.04) 0.2132 19.11 (5.79) 19.78 (6.90) 0.8243
mRNA means and SD are presented as fold-change; protein levels are measured in picograms per microgram. ap value for t test comparing HR to control; mRNA is
log-transformed; bp value for t test comparing early stage to late stage; mRNA is log-transformed.
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therapeutic trial of any psychotropic medication.Gene expression (mRNA) and protein levels of
candidate genes
As presented in Table 1, using unadjusted t tests for com-
paring two independent groups, there were no significant
differences in the mRNA expression levels of candidate
genes between high-risk and control offspring or between
high-risk offspring in the early compared to those in later
clinical stages of illness development; however, compared
to controls, high-risk offspring had higher IL-6 (p = 0.050)
and BDNF (p = 0.006) protein levels. In addition, earlier
stage high-risk offspring had higher IL-6 and BDNF protein
levels compared to high-risk offspring in the later stages ofFigure 1 BDNF log mRNA expression (a) and protein levels (b) in conBD development (p = 0.050; p = 0.045) (see Figures 1 and 2
for box plots).
Using a linear regression model adjusting for sex, age,
GAF, and SES, there was a significant difference between
high-risk and control offspring in BDNF protein levels
(p = 0.026). It was estimated that high-risk offspring had
136.67 pg/μg higher mean BDNF protein levels than
controls. After adjustment, there was no evidence of dif-
ferences between high-risk and control offspring for any
other proteins examined (p(TNF) = 0.377, p(IFN) = 0.226,
p(IL-6) = 0.172, p(IL-10) = 0.547) or mRNA expression levels
(p(BDNF) = 0.274, p(TNF) = 0.229, p(IFN) = 0.115, p(IL-6) = 0.184,
p(IL-10) = 0.731).
When comparing high-risk offspring in early clinical
stages to high-risk offspring in later clinical stages after
adjustment, there were no differences in protein levelstrol and high-risk early and later stages of illness development.
Figure 2 IL-6 log mRNA expression (a) and protein levels (b) in control and high-risk early and later stages of illness development.
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0.151, p(IL-10) = 0.929) or mRNA expression (p(BDNF) =
0.691, p(TNF) = 0.376, p(IFN) = 0.321, p(IL-6) = 0.840, p(IL-10) =
0.796) in all markers examined.
Moderating effects of genetic variants on high-risk status
for gene expression and protein levels
As indicated in Table 2, for log mRNA expression, there
was a significant interaction between the BDNF genotype
and high-risk status after adjustments (p = 0.028). In par-
ticular, among those with the VAL/VAL genotype, the
high-risk group (n = 9) had higher log mRNA expression
levels than the control group (n = 10) (p = 0.024). In the
high-risk group, those with the VAL/VAL genotype had
higher log mRNA expression than those carrying a MET
allele (n = 8) (p = 0.003) (see Additional file 1: Table S2a
for pair-wise comparisons)
There was also a significant interaction for protein
levels between the BDNF genotype and high-risk status
after adjustments (p = 0.040). In particular, among those
with the VAL/VAL genotype, the high-risk group had
higher protein levels than the control group (p = 0.004).
In the high-risk group, those with the VAL/VAL geno-
type had higher protein levels than MET carriers (p =Table 2 Interaction between genotype and high-risk status an
Genotype × high-risk status
predicting log mRNA expression
Genotype × high-risk stat
predicting protein level






log mRNA expression presented as log fold-change; protein levels are measured in0.030) (see Additional file 1: Table S2b for pair-wise
comparisons and Figure 3).
For IL-6, high-risk offspring with the GG variant
(n = 14) had higher protein levels than control off-
spring (n = 9) after adjustments (p = 0.035). However,
the global F test for interaction between the IL-6 geno-
type and high-risk status (providing some protection
for multiple comparisons) was not significant (p = 0.159)
(see Table 2).
Moderating effects of genetic variants on stage of illness
development for gene expression and protein levels
As indicated in Table 2, for log mRNA expression levels,
there was marginal significance of an interaction be-
tween the BDNF genotype and illness development stage
after adjustments (p = 0.063). In the early stage of illness
development, those high-risk offspring with a VAL/VAL
genotype (n = 6) had higher mRNA expression levels
than those high-risk offspring who were MET carriers
(n = 4) (p = 0.003). Among those high-risk offspring who
were MET carriers, those in the later stages of illness devel-
opment (n = 4) had higher mRNA expression than those in
the earlier stages (n = 4) (p = 0.038) (see Additional file 1:
Table S2c for pair-wise comparisons).d genotype and clinical stage
us
s
Genotype × clinical stage
predicting log mRNA expression
Genotype × clinical stage
predicting protein levels






picograms per microgram. All values are adjusted for sex, age, SES, and GAF.
a b
Figure 3 BDNF log mRNA expression (a) and protein levels (b) in high-risk and control offspring. MET genotype (blue lines) and VAL/VAL
genotype (red lines)*.
Duffy et al. International Journal of Bipolar Disorders 2014, 2:4 Page 5 of 9
http://www.journalbipolardisorders.com/content/2/1/4For TNF, among those high-risk offspring in the early
stages of illness development, those with a GG genotype
(n = 8) had higher log mRNA expression than those with
an AG genotype (n = 2) after adjustments (p = 0.016).
Also, among those high-risk offspring with the GG
genotype, those in the early stages of illness development
had higher log mRNA expression than those in the later
stages (n = 6) after adjustments (p = 0.024). However, the
overall interaction test was not significant (p = 0.144).
As indicated in Table 2, for protein levels, there was
marginal significance of an interaction between the IL-6
genotype and illness stage after adjustments (p = 0.069).
Among those with a GG genotype, high-risk offspring in
the earlier stages of illness development (n = 6) had higher
protein levels than those in the later stages of illness devel-
opment (n = 1) (p = 0.057). There was no evidence of pair-
wise differences in BDNF protein levels (see Additional
file 1: Table S2d for pair-wise comparisons).
In high-risk offspring in the later stages of illness de-
velopment, those with an AG genotype (n = 4) had sig-
nificantly higher IL-10 protein levels than those with an
AA genotype (n = 3) after adjustments (p = 0.046). How-
ever the overall interaction test was not significant (p =
0.310) (Table 2).
Discussion
There has been a substantial literature linking mood dis-
orders with altered immune functioning, in at least a
subset of patients. Acute mood episodes are associated
with an inflammatory bias, and effective antidepressantand mood-stabilizing treatments have been shown to
restore the balance between pro- and anti-inflammatory
mediators (Raison and Miller 2011). Patients with acute
mood episodes are at increased risk of developing
systemic inflammatory illnesses, and patients with
inflammatory-based illnesses have a higher risk of deve-
loping mood disorders (Connor and Leonard 1998). Fur-
thermore, there have been recent reports of a shift in the
balance of immune and neurotrophic mediators over the
course of established BD, suggesting the development of a
more severe dysregulation in the immune system and re-
duction in neurotrophic factors in patients with recurrent
episodes of illness, poor remission, and a high burden of
illness (Berk et al. 2011; Kauer-Sant'Anna et al. 2009).
Interestingly, there is accruing evidence that increased
pro-inflammatory markers and related HPA axis dysreg-
ulation are detectable early in the developing course of
bipolar illness in genetically high-risk adolescents, even
before the onset of the first major mood episodes (Duffy
et al. 2012). In this investigation, we studied DNA poly-
morphisms, gene expression, and protein levels of pro-
inflammatory mediators IL-1β, IL-6, TNF-α, and IFN-δ,
anti-inflammatory mediator IL-10, and BDNF in lym-
phocytes and plasma collected from offspring at genetic
high risk compared to low-risk offspring. We divided the
high-risk offspring into two groups based on their place
in a clinical staging model describing the development
of bipolar illness (Duffy et al. 2010).
We found differences in protein levels in candidate genes
related to inflammation and neuroprotection between
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son to low-risk controls. Specifically, both IL-6 and
BDNF protein levels were higher in high-risk compared
to low-risk offspring. We also found that protein levels
of candidate genes changed over the clinical stages of
illness development. Specifically, we found a significant
difference in IL-6 and BDNF protein levels between
high-risk offspring in the early compared to the later
stages of illness development. While only differences be-
tween high-risk and control offspring for BDNF protein
levels remained significant after adjustment, this was
likely due to the small sample size. These findings sup-
port the hypothesis that there are detectable differences
in immune and neurotrophic markers in high-risk indi-
viduals and that these change over the course of illness
development. This hypothesis requires systematic longi-
tudinal investigation within high-risk subjects over the
early clinical stages of illness development.
We also found that the genotype of high-risk individ-
uals significantly influences the association between
high-risk status and clinical stage of illness development
for both gene expression and protein levels. Specifically,
in this study, there was a significant interaction between
the BDNF genotype and high-risk status for both gene
expression and protein levels. The VAL/VAL genotype
has been associated with early-onset mood disorders
(Strauss et al. 2004). In a recent study, Goodyer et al.
(2010) found an interaction between elevated morning
cortisol and presence of the VAL/VAL genotype in pre-
dicting increased risk of depression in high-risk adoles-
cents, underscoring the importance of an integrative
perspective when interpreting the moderating effects of
gene variants on illness outcome.
Interestingly, there were also significant interactions
found in this study between the clinical stage of illness de-
velopment and BDNF and IL-6 genotypes, for both gene
expression and protein levels, respectively. This observa-
tion is consistent with other reports in patients with well-
established BD of an association between clinical course
and changes in the balance of pro-inflammatory mediators
and neurotrophic factors (Kauer-Sant'Anna et al. 2009).
The key point from our findings is that changes in bio-
markers seem to occur over the course of illness develop-
ment, as well as in association with burden of illness
effects.
The major limitation of this study is the small number
of high-risk and comparison offspring, as well as the
cross-sectional study design. Therefore, findings should
be viewed as preliminary and hypothesis generating.
However, all subjects included in this study have been
repeatedly prospectively assessed in clinical interviews,
and their parents have been studied longitudinally to en-
sure stability of diagnosis (i.e., high-risk status). Further-
more, there was minimal confounding with exposure tomedication. Undoubtedly, a longitudinal design tracking
changes in candidate biomarkers within high-risk subjects
over illness development would be a much more powerful
approach to understand the pathophysiology underlying
illness development and to validate and refine the clinical
stages. However, given the limitations discussed, this study
does provide evidence suggesting that there are identifi-
able differences in mRNA expression and protein levels in
candidate immune and neurotrophic peripheral markers
in high-risk offspring, which are moderated by genetic
variants. Also, there appear to be changes in candidate
biological markers across the clinical stages of illness de-
velopment. However, we emphasize that these findings are
preliminary and require systematic longitudinal study in a
larger well-characterized high-risk cohort.
Conclusions
It is increasingly acknowledged that an important way
forward is to invest in studies aimed at identifying genet-
ically sensitive biological makers that relate to etiological
processes, treatment response, and longer-term out-
comes (Goodyer et al. 2010). The success of such re-
search is predicated on starting with well-characterized
high-risk samples to reduce heterogeneity. In order to
provide an integrated view, it would be prudent to include
a number of associated physiological makers indexing
interactive immune and neuroendocrine pathways. In this
way, genetically sensitive pathways associated with the eti-
ology of BD can be separated from the burden of illness
effects related to recurrent episodes, psychotic symptoms,
treatment, and medical and psychiatric complications.
This research would lead to a comprehensive working
model of how BD develops in genetically at-risk individ-
uals and refine the clinical staging model, while identifying
novel stage-specific targets for intervention and preven-
tion of illness progression.
Methods
Subjects
In compliance with the Helsinki Declaration, this re-
search was approved by local research ethics boards in
Ottawa, Halifax, and Calgary.
In this study, we recruited 19 high-risk and 16 compari-
son offspring from families participating in an ongoing lon-
gitudinal study describing the early natural history of BD
(MOP 102761) (Duffy et al. 2009, 2010). Specifically, we
enrolled consenting adolescent and young adult offspring
from parents with BD based on Schedule for Affective
Disorders - Lifetime Version (SADS-L) interview con-
ducted by a research psychiatrist and final DSM-IV
diagnosis confirmed by blind consensus review using all
available clinical information (other parents no lifetime
history of major psychiatric disorders). Consenting
comparison offspring were recruited from families in
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major psychiatric disorder (psychotic, mood, substance
use disorders) on the basis of SADS-L interviews and
blind consensus diagnostic review.
As part of the ongoing longitudinal study, all offspring
were clinically assessed annually using KSADS-PL format
interviews conducted by a psychiatrist. Final DSM-IV
diagnoses were confirmed on the basis of blind consensus
review including two additional experienced clinician
researchers (one being a senior research psychiatrist)
using all available clinical information. At the time of
blood sampling, all subjects were at their best level of
functioning (well or in remission) and completed the
Beck Depression Inventory (BDI) (Beck and Beamesderfer
1974) and the clinician completed the Global Assess-
ment of Functioning Scale (GAF) (Hall 1995). Subjects
were excluded from this study if they were acutely
psychiatrically or medically ill, abusing substances, or
taking anti-inflammatory medications (i.e., prednisone,
ASA, steroid inhalers) within 6 months of sampling.
We used a novel clinical staging model to subdivide
high-risk subjects into those in the early or later stages
of bipolar illness development (see Duffy et al. 2010,
2014). Briefly, high-risk offspring were classified as fol-
lows: stage 0 if they were clinically well; stage 1 if they
met lifetime criteria for non-specific disorders (ADHD,
anxiety, sleep); stage 2 if they met lifetime criteria for
sub-affective mood disorders (dysthymia, depression
NOS, adjustment disorder with anxiety and depressive
symptoms); stage 3 if they met lifetime criteria for major
depressive disorder (single episode or recurrent); and
stage 4 if they met lifetime criteria for a diagnosable BD
(BDNOS, BD I or II, schizoaffective-BD). For this ana-
lysis, we defined early stage illness as stages 0 to 2 and
later stage illness development as stages 3 to 4, given




Twenty milliliters of blood was drawn from each subject
by venipuncture into a free-anticoagulant vacuum tube.
Ficoll-Paque PLUS (71-7167-00 AG, GE Healthcare,
Uppsala, Sweden) was used to extract white blood cells.
Briefly, 4 ml of diluted blood (1:1) was carefully layered
on 4 ml of Ficoll-Paque followed by centrifugation at
400 g for 40 min. First, plasma was removed and then
the lymphocyte ring was carefully extracted. Lympho-
cytes were washed with balanced salt solution three
times. Plasma and lymphocytes were kept frozen at −80°C
until assayed. Lymphocytes samples were used to ex-
tract DNA and RNA for genotyping and mRNA ex-
pression studies, and plasma was used to evaluate the
protein levels. All samples were de-identified and codedat the time of sample collection, and the laboratory
remained blind to the study group and family affiliation.
Gene expression
For the gene expression study, a two-step reverse tran-
scription polymerase chain reaction (RT-PCR) was per-
formed. Miniprep columns were used to isolate RNA
from lymphocytes according to the manufacturer's proto-
col (RNeasy® by Qiagen, Venlo, The Netherlands). RNA
concentrations were determined using a NanoDrop™ 1000
Spectrophotometer System® (Thermo Scientific, Wilming-
ton, DE, USA); 0.5 μg of total RNA was reverse-
transcribed to generate high-fidelity cDNA employing a
kit from the same manufacturer (QuantiTect® Reverse
Transcription Kit). Assuming a 1:1 conversion of RNA to
cDNA, 15 ng of cDNA was used to perform qPCR with a
commercial mix (QuantiFast® SYBR® Green PCR Kit by
Qiagen). All primers were designed spanning an exon/
exon boundary to eliminate amplification of contaminat-
ing genomic DNA (QuantiTect® Primers by Qiagen).
Thermal cycling conditions were as follows: 1 cycle of
5 min at 95°C (hot start step), 40 cycles of 10 s at 95°C
followed by 30 s at 60°C, and finally a melting curve ran-
ging from 65°C to 95°C. Real-time RT-PCR amplifica-
tions were run on a CFX 96™ Real-Time PCR Detection
System (Bio-Rad, Hercules, CA, USA) within a 25-μl final
volume reaction. All reactions were performed in duplicate
per experiment, and β-actin was included in all experi-
ments as an endogenous control. Data were expressed as
cycle threshold (CT) values being normalized against
β-actin. Gene expression results were calculated using the
2−ΔΔCT relative quantification method. The primer IDs used
were as follows: HsBDNF1SG, HsIL101SG, HsTNF3SG,
HsIFNG1SG, HsIL61SG.
Protein levels
Protein levels of IL-10, IL-6, TNF-alpha, IFN, and BDNF
were assessed by sandwich ELISA, using a commercial kit
according to the manufacturer's instructions (Cedarlane
(Burlington, Canada): IL-10 #CL76130, IL-6 #CL76126K,
TNF-alpha #CL76145K, IFN #CL76120K; Millipore
(Billerica, MA, USA): BDNF #CYT306).
DNA genotyping
Genomic DNA was extracted from lymphocyte samples
using a Miniprep column system (GenEluteTM Mamma-
lian Genomic DNA Miniprep Kit by Sigma, St. Louis,
MO, USA). DNA concentrations were determined apply-
ing the same system used previously for the gene expres-
sion experiment.
Amplification: 20 ng of DNA
Twenty nanograms of DNA was amplified for each sam-
ple for seven variants across six using TaqMan®. The
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in a total volume of 10 μl. For each variant, six no tem-
plate control (NTC) samples were run simultaneously
for quality control purposes. Post-amplification products
were visualized on the ViiA™ 7 Real-Time PCR System,
and genotype calls were assigned manually.
Statistical approach
Unadjusted differences between groups were tested using
t tests and, where noted, Fisher's exact tests. Linear regres-
sion models were used to test for differences between
groups and for interactions between group and DNA vari-
ant, after adjustment for sex, age, socio-economic status
(SES), and GAF. When conducting t tests and linear re-
gression analysis, mRNA expression levels were log-
transformed in order to satisfy the normality assumption.
All DNA variant allele combinations were treated as cat-
egorical with three levels for each marker, with the excep-
tion of BDNF, which was treated as a binary variable
representing the presence or absence of a MET DNA vari-
ant. No adjustments for multiple comparisons were made.
Analyses were conducted using SAS version 9.3.
Supplementary tables
To elucidate interactions between group and DNA vari-
ant, t tests for specific contrasts (pair-wise differences)
in the least squares means were performed.
Additional file
Additional file 1: Supplementary tables. Table S1. Clinical variables
in high-risk offspring with a lifetime mood disorder (clinical stage 3-4).
Table S2a. Differences in BDNF log mRNA expression between high-risk
and control offspring with and without the MET variant. Table S2b.
Differences in BDNF protein levels between high-risk and control offspring
with and without the MET variant. Table S2c. Differences in BDNF log
mRNA expression between early and late stage illness in high-risk offspring
with and without the MET variant. Table S2d. Differences in BDNF protein
levels between early and late stage illness in high-risk offspring with and
without the MET variant.
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